{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:54:12Z","timestamp":1785430452434,"version":"3.56.0"},"reference-count":47,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"College of Science and Technology at North Carolina A&T State University","award":["GRADS-4C"],"award-info":[{"award-number":["GRADS-4C"]}]},{"award":["GRADS-4C"],"award-info":[{"award-number":["GRADS-4C"]}],"id":[{"id":"https:\/\/ror.org\/02aze4h65","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R16NS147983-01"],"award-info":[{"award-number":["1R16NS147983-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thomas A. Pappas Chair in Neurosciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MPs"],"abstract":"<jats:p>Glioblastoma (GBM) is an aggressive primary brain tumor associated with poor prognosis and resistance to therapy, underscoring the need for reliable preclinical models to evaluate emerging treatments. The orthotopic implantation of GBM stem-like cells (GSCs), combined with the intratumoral delivery of therapeutic agents, represents a widely used approach for modeling GBM tumor growth and studying treatment response. In particular, oncolytic herpes simplex viruses (oHSVs) have emerged as a promising strategy to selectively target malignant cells while inducing antitumor immune responses with minimal systemic toxicity. However, performing repeated survival stereotactic neurosurgeries in the same animal poses significant technical challenges. Here, we describe a comprehensive and reproducible protocol for triple survival stereotactic neurosurgery in mice. This approach involves (i) the intracranial implantation of GSCs to establish orthotopic tumors, (ii) the intratumoral delivery of oHSV using the same stereotactic coordinates, and (iii) contralateral intracranial rechallenge with GSCs to evaluate therapeutic efficacy and resistance to tumor rechallenge as a measure of immune memory. Using this protocol, consistent tumor establishment was achieved, and mice tolerated repeated neurosurgical procedures with stable postoperative recovery. Successful intracranial rechallenge in the same animal demonstrates the technical feasibility of multiple survival surgeries while minimizing procedure-related variability and complications. This method enables longitudinal assessment of tumor progression, therapeutic response, and durable memory protection within a single subject. Furthermore, this protocol provides a versatile platform for evaluating oncolytic virotherapy and other localized treatment strategies for GBM.<\/jats:p>","DOI":"10.3390\/mps9030082","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:08:02Z","timestamp":1780535282000},"page":"82","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triple-Survival Stereotactic Brain Surgeries for the Intracranial Injections of Glioblastoma Stem-like Cells and Oncolytic Herpes Simplex Viruses"],"prefix":"10.3390","volume":"9","author":[{"given":"Sourav","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Department of Biology, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Biology, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-6790","authenticated-orcid":false,"given":"Checo J.","family":"Rorie","sequence":"additional","affiliation":[{"name":"Department of Biology, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2795","authenticated-orcid":false,"given":"Samuel D.","family":"Rabkin","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8225-241X","authenticated-orcid":false,"given":"Hiroaki","family":"Wakimoto","sequence":"additional","affiliation":[{"name":"Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9923-5533","authenticated-orcid":false,"given":"Dipongkor","family":"Saha","sequence":"additional","affiliation":[{"name":"Department of Biology, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sipos, D., Raposa, B.L., Freihat, O., Simon, M., Mekis, N., Cornacchione, P., and Kovacs, A. (2025). Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes. Cancers, 17.","DOI":"10.3390\/cancers17010146"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tang, X., Zuo, C., Fang, P., Liu, G., Qiu, Y., Huang, Y., and Tang, R. (2021). Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.701291"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: Current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11060-023-04536-8","article-title":"Understanding current experimental models of glioblastoma-brain microenvironment interactions","volume":"166","author":"Yadav","year":"2024","journal-title":"J. Neurooncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1038\/s41467-020-17704-5","article-title":"Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types","volume":"11","author":"Khalsa","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/gt.2012.62","article-title":"Oncolytic measles virus strains have significant antitumor activity against glioma stem cells","volume":"20","author":"Allen","year":"2013","journal-title":"Gene Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: Advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2024.12.054","article-title":"Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development","volume":"33","author":"Ayele","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47Delta: First Approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12006","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model","volume":"110","author":"Cheema","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/humc.2013.201","article-title":"Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates","volume":"25","author":"Roth","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41467-024-55455-9","article-title":"Oncolytic reprogramming of tumor microenvironment shapes CD4 T-cell memory via the IL6ra-Bcl6 axis for targeted control of glioblastoma","volume":"16","author":"Grimes","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, H., Borlongan, M., Kaufman, H.L., Le, U., Nauwynck, H.J., Rabkin, S.D., and Saha, D. (2024). Cytokine-armed oncolytic herpes simplex viruses: A game-changer in cancer immunotherapy?. J. Immunother. Cancer, 12.","DOI":"10.1136\/jitc-2023-008025"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2217\/imt-2018-0009","article-title":"Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma","volume":"10","author":"Saha","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1158\/1078-0432.CCR-17-1717","article-title":"Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models","volume":"24","author":"Saha","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Saha, D., Rabkin, S.D., and Martuza, R.L. (2020). Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2019-000345"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.neuron.2012.03.017","article-title":"Whole-brain mapping of direct inputs to midbrain dopamine neurons","volume":"74","author":"Zhu","year":"2012","journal-title":"Neuron"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymeth.2025.03.005","article-title":"Two minimally invasive strategies to implant guide cannulas for multiple injections in deep brain areas","volume":"238","author":"Bartoletti","year":"2025","journal-title":"Methods"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1016\/j.ymthe.2025.08.028","article-title":"Intratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity","volume":"33","author":"Lunavat","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bommareddy, P.K., Wakimoto, H., Martuza, R.L., Kaufman, H.L., Rabkin, S.D., and Saha, D. (2024). Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. J. Immunother. Cancer, 12.","DOI":"10.1136\/jitc-2024-008880"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1038\/nprot.2006.450","article-title":"Stereotaxic gene delivery in the rodent brain","volume":"1","author":"Cetin","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_23","first-page":"57270","article-title":"Stereotaxic Surgery for Genetic Manipulation in Striatal Cells of Neonatal Mouse Brains","volume":"137","author":"Chen","year":"2018","journal-title":"J. Vis. Exp."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4939-8799-3_17","article-title":"Stereotaxic Surgery and Viral Delivery of Zinc-Finger Epigenetic Editing Tools in Rodent Brain","volume":"1867","author":"Hamilton","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-0716-4051-7_16","article-title":"Stereotaxic Surgery as a Method to Deliver Epigenetic Editing Constructs in Rodent Brain","volume":"2842","author":"Heller","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-3271-9_14","article-title":"Intraparenchymal Stereotaxic Delivery of rAAV and Special Considerations in Vector Handling","volume":"1382","author":"Benskey","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Keiser, M.S., Chen, Y.H., and Davidson, B.L. (2018). Techniques for Intracranial Stereotaxic Injections of Adeno-Associated Viral Vectors in Adult Mice. Curr. Protoc. Mouse Biol., 8.","DOI":"10.1002\/cpmo.57"},{"key":"ref_28","first-page":"10","article-title":"Stereotaxic Surgical Approach to Microinject the Caudal Brainstem and Upper Cervical Spinal Cord via the Cisterna Magna in Mice","volume":"179","author":"Joshi","year":"2022","journal-title":"J. Vis. Exp."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"22166","DOI":"10.1038\/s41598-025-05328-y","article-title":"Modified stereotactic neurosurgery techniques for rodent surgery enhance survival and reduce surgery time in a severe traumatic brain injury model","volume":"15","author":"Wechakarn","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Mart\u00edn, E., Coto-Vilcapoma, A., Castilla-Silgado, J., Rodr\u00edguez-Ca\u00f1\u00f3n, M., Prado, C., \u00c1lvarez, G., \u00c1lvarez-Vega, M.A., Fern\u00e1ndez-Garc\u00eda, B., Men\u00e9ndez-Gonz\u00e1lez, M., and Tom\u00e1s-Zapico, C. (2023). Refining Stereotaxic Neurosurgery Techniques and Welfare Assessment for Long-Term Intracerebroventricular Device Implantation in Rodents. Animals, 13.","DOI":"10.3390\/ani13162627"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.1863","article-title":"Development of a novel mouse glioma model using lentiviral vectors","volume":"15","author":"Marumoto","year":"2009","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12974-018-1212-7","article-title":"Targeted intracerebral delivery of the anti-inflammatory cytokine IL13 promotes alternative activation of both microglia and macrophages after stroke","volume":"15","author":"Hoornaert","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"115790","DOI":"10.1016\/j.biopha.2023.115790","article-title":"Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model","volume":"173","author":"Park","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_34","first-page":"493","article-title":"Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment","volume":"19","author":"Hardcastle","year":"2017","journal-title":"Neuro. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kleijn, A., Kloezeman, J., Treffers-Westerlaken, E., Fulci, G., Leenstra, S., Dirven, C., Debets, R., and Lamfers, M. (2014). The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097495"},{"key":"ref_36","first-page":"10","article-title":"Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus","volume":"171","author":"Nguyen","year":"2021","journal-title":"J. Vis. Exp."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ilar\/ilab016","article-title":"Mouse Anesthesia: The Art and Science","volume":"62","author":"Navarro","year":"2021","journal-title":"ILAR J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/DDDT.S467835","article-title":"Development of Intratumoral Drug Delivery Based Strategies for Antitumor Therapy","volume":"18","author":"Jiang","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Xia, Y., Li, D., Yang, K., and Ou, X. (2025). Systemic Delivery Strategies for Oncolytic Viruses: Advancing Targeted and Efficient Tumor Therapy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146900"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1089\/hum.2016.038","article-title":"Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2017.02.001","article-title":"Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates","volume":"5","author":"Cassady","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-21-2636","article-title":"Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study","volume":"28","author":"Miller","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.cell.2025.12.055","article-title":"Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial","volume":"189","author":"Meylan","year":"2026","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"}],"container-title":["Methods and Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-9279\/9\/3\/82\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:10:22Z","timestamp":1780539022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-9279\/9\/3\/82"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["mps9030082"],"URL":"https:\/\/doi.org\/10.3390\/mps9030082","relation":{},"ISSN":["2409-9279"],"issn-type":[{"value":"2409-9279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}